Finance Watch: $320m In New VC Deals Includes $110m Round For Neogene
Also, Recursion Raises $239m, Including $50m From New Partner Bayer
Executive Summary
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
You may also be interested in...
Israel VC Backs MiNA's Novel SaRNAs In Cancer, And Add-On Therapy Areas
Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.
Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike
VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.
Need a specific report? 1000+ reports available
Buy Reports